Skip to main content

Peer Review reports

From: Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter study

Original Submission
29 Mar 2016 Submitted Original manuscript
28 Oct 2016 Author responded Author comments - Bernies van der Hiel
Resubmission - Version 2
28 Oct 2016 Submitted Manuscript version 2
14 Jul 2017 Author responded Author comments - Bernies van der Hiel
3 Jul 2017 Reviewed Reviewer Report - Robert R. McWilliams
1 Jun 2017 Reviewed Reviewer Report - Hussein A Tawbi
Resubmission - Version 3
14 Jul 2017 Submitted Manuscript version 3
25 Aug 2017 Author responded Author comments - Bernies van der Hiel
4 Aug 2017 Reviewed Reviewer Report - Robert R. McWilliams
Resubmission - Version 4
25 Aug 2017 Submitted Manuscript version 4
Publishing
28 Aug 2017 Editorially accepted
15 Sep 2017 Article published 10.1186/s12885-017-3626-5

You can find further information about peer review here.

Back to article page